Evidence map›Paper›PMID 40839323›Full record

ArticleApoptosis : an international journal on programmed cell death2025

Dual-functional Anti-hPSMA

Heng Yang, Jian He, Yujun Chen, Xiaochen Zhou, Xiaofeng Cheng, Zhenhao Zeng, Min Zhou, Gongxian Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Heng Yang *Jiangxi Institute of Urology, Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwai Zhengjie, Donghu District, Nanchang City, 330006, Jiangxi Province, China.
Jian He *University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine , Zhejiang University, No.718, Haizhou East Road, Haining, 314400, Zhejiang Province, China.
Yujun Chen *Jiangxi Institute of Urology, Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwai Zhengjie, Donghu District, Nanchang City, 330006, Jiangxi Province, China.
Xiaochen ZhouJiangxi Institute of Urology, Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwai Zhengjie, Donghu District, Nanchang City, 330006, Jiangxi Province, China.
Xiaofeng ChengWuhan Integrated Traditional Chinese and Western Medicine Hospital (Wuhan First Hospital), Institute of Urology, Wuhan, 430000, Hubei, China.
Zhenhao ZengDepartment of Urology, Jiangxi Provincial People's Hospital, Nanchang, 330006, Jiangxi, China.
Min ZhouUniversity-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine , Zhejiang University, No.718, Haizhou East Road, Haining, 314400, Zhejiang Province, China. zhoum@zju.edu.cn.
Gongxian WangJiangxi Institute of Urology, Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwai Zhengjie, Donghu District, Nanchang City, 330006, Jiangxi Province, China. wanggx-mr@126.com.

Funding

the National Natural Science Foundation of China No. 82060467, 81460389
6 · The paper itself

Abstract

Addressing prostate cancer, particularly in its aggressive forms, poses challenges that call for innovative treatment modalities. Our research focuses on developing a nanotechnological solution to enhance targeted cancer therapy. We have synthesized advanced nanocapsules embedded with indocyanine green (ICG) and conjugated with the Anti-hPSMA

Indexed as

NanocapsulesProstatic NeoplasmsAnimalsApoptosisCell Line, TumorHumansIndocyanine GreenMaleMicePhotochemotherapyXenograft Model Antitumor AssaysIndocyanine GreenNanocapsulesAnti-hPSMAEC domain-CS@ICG nanocapsulesPhotodynamic therapyPhotothermal therapyProstate cancerSpecific targeting

Identifiers

PMID40839323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.